Cilostazol

Generic Name
Cilostazol
Brand Names
-
Drug Type
Small Molecule
Chemical Formula
C20H27N5O2
CAS Number
73963-72-1
Unique Ingredient Identifier
N7Z035406B
Background

Cilostazol is a quinolinone derivative and antiplatelet agent with vasodilating properties that has been used in the symptomatic treatment of intermittent claudication in patients with peripheral ischaemia. It is marketed under the brand name Pletal by Otsuka Pharmaceutical Co.. Cilostazol works by inhibiting both primary and secondary aggregation and reduci...

Indication

Indicated for the alleviation of symptoms of intermittent claudication (pain in the legs that occurs with walking and disappears with rest).

Associated Conditions
Intermittent Claudication
Associated Therapies
-
Clinical Trials
Related News

Retina is a Marker for Cerebrovascular Heath

First Posted Date
2021-02-15
Last Posted Date
2024-07-05
Lead Sponsor
Mayo Clinic
Target Recruit Count
100
Registration Number
NCT04753970
Locations
🇺🇸

Mayo Clinic Florida, Jacksonville, Florida, United States

The Effect of Anti-calcitonin Gene-related Peptide (CGRP) Receptor Antibodies on the Headache Inducing Properties of CGRP and Cilostazol in Migraine Patients

First Posted Date
2020-07-01
Last Posted Date
2020-10-08
Lead Sponsor
Danish Headache Center
Target Recruit Count
72
Registration Number
NCT04452929
Locations
🇩🇰

Danish Headache Center, Glostrup, Denmark

Oxford Haemodynamic Adaptation to Reduce Pulsatility Trial

First Posted Date
2019-02-26
Last Posted Date
2023-02-24
Lead Sponsor
University of Oxford
Target Recruit Count
75
Registration Number
NCT03855332
Locations
🇬🇧

University of Oxford, Oxford, Oxon, United Kingdom

Comparison of Two Different Antiplatelet Preparations for an Unruptured Intracranial Aneurysm

First Posted Date
2018-07-10
Last Posted Date
2022-04-27
Lead Sponsor
Seoul National University Hospital
Target Recruit Count
198
Registration Number
NCT03581409
Locations
🇰🇷

Seoul National Univeristy Bundang Hospital, Seongnam-si, Gyeonggi-do, Korea, Republic of

LACunar Intervention (LACI-2) Trial-2

First Posted Date
2018-03-02
Last Posted Date
2024-11-11
Lead Sponsor
University of Edinburgh
Target Recruit Count
363
Registration Number
NCT03451591
Locations
🇬🇧

Royal Infirmary, Edinburgh, Lothian, United Kingdom

Effect of Cilostazol on Carotid Atherosclerosis Estimated by 3D Ultrasound in Patients With Type 2 Diabetes

First Posted Date
2017-08-14
Last Posted Date
2020-04-08
Lead Sponsor
Seoul National University Bundang Hospital
Target Recruit Count
50
Registration Number
NCT03248401
Locations
🇰🇷

Seoul National University Bundang Hospital, Seongnam, Gyeonggi, Korea, Republic of

Diabetic Artery Obstruction: is it Possible to Reduce Ischemic Events With Cilostazol?

First Posted Date
2016-12-06
Last Posted Date
2020-12-29
Lead Sponsor
University of Ioannina
Target Recruit Count
826
Registration Number
NCT02983214
Locations
🇬🇷

Atherothrombosis Research Centre / Laboratory of Biochemistry, University of Ioannina, Ioannina, Epirus, Greece

Effect of aSpirin Versus CilOstazol for Inhibition of Antiplatelet aggRegaTion in Type 2 DM Patients

First Posted Date
2016-10-14
Last Posted Date
2016-10-14
Lead Sponsor
Kangbuk Samsung Hospital
Target Recruit Count
116
Registration Number
NCT02933788

Cilostazol Following Peripheral Endovascular Procedures

First Posted Date
2016-05-12
Last Posted Date
2021-01-12
Lead Sponsor
Attikon Hospital
Target Recruit Count
200
Registration Number
NCT02770274
Locations
🇬🇷

Patras Universityu Hospital, Patras, Achaia, Greece

🇬🇷

Attikon university General Hospital, Athens, Attiki, Greece

Pharmacodynamic Study of Cilostazol in Healthy Volunteers

First Posted Date
2015-09-18
Last Posted Date
2021-10-13
Lead Sponsor
Otsuka Pharmaceutical Co., Ltd.
Target Recruit Count
77
Registration Number
NCT02554721
© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy